Effect of Sulodexide on Urinary Biomarkers of Kidney Injury in Normoalbuminuric Type 2 Diabetes: A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20140806001

Enrollment

Unknown

Registered

2014-08-06

Start date

2013-08-02

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy Glycosaminoglycans Diabetic nephropathy Urine transforming growth factor&#45

Interventions

Sulodexide is a formulation composed of the two glycosaminoglycans (80% fast&#45

moving heparin and 20% dermatan sulfate.,

Active Comparator Drug,Placebo Comparator Drug

Soludexide,Placebo

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: type 2 diabetes patients with normoalbuminuria stable standard treatment with anti glycemic agents and RAAS inhibitors within three months before starting the study

Exclusion criteria

Exclusion criteria: type 1 diabetes active malignancy severe heart lung or liver disease stroke chronic infection e g tuberculosis within one year of starting the study and any immunological or inflammatory disorders

Design outcomes

Primary

Measure	Time frame
urinary transforming growth factor-beta1 14 weeks ELISA	—

Secondary

Measure	Time frame
urine albumin 14 weeks immunoturbidimetric method	—

Countries

Thailand

Contacts

Public ContactBancha Satirapoj

Phramongkutklao Hospital and College of Medicine

satirapoj@yahoo.com026444676

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026